Advertisement

Immunomodulators

  • Li Cher Loh
  • Neil C. Barnes
Chapter
  • 87 Downloads
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Airway inflammation is fundamental to the disease process in chronic asthma. Different components of the immune system play important roles in perpetuating and orchestrating this inflammatory response. Many types of cells are involved, the airway epithelium is shed; eosinophils, T lymphocytes, polymorphonuclear cells, mast cells, and macrophages are present in an activated state and release proinflammatory mediators, cytokines and growth factors. From inflammation, a process of healing and repair may follow and this has been postulated to lead to remodeling of the airways.

Keywords

Mast Cell Airway Inflammation Severe Asthma Immunosuppressive Agent Allergy Clin Immunol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Corrigan C, Kay AB (1992) T cells and eosinophils in the pathogenesis of asthma. Immunol Today 13: 501–507PubMedCrossRefGoogle Scholar
  2. 2.
    Marone G, Columbo M, Galeone D, Guidi G, Kagey-Sobotka A, Lichtenstein LM et al (1986) Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin. Agents Actions 18: 100–102PubMedCrossRefGoogle Scholar
  3. 3.
    Bernstein DI, Bernstein IL, Bodenheimer SS, Pietrusko RG (1988) An open study of auranofin in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 81: 6–16PubMedCrossRefGoogle Scholar
  4. 4.
    Nierop G, Gitjzel WP, Bel EH, Zwinderman AH, Dijkman KH (1992) Auranofin in the treatment of steroid-dependent asthma: a double blind study. Thorax 47: 349–354PubMedCrossRefGoogle Scholar
  5. 5.
    Honma M, Tamura G, Shirato K, Takishima T (1994) Effect of an oral gold compound auranofin, on non-specific bronchial hyper-responsiveness in mild asthma. Thorax 49: 649–651PubMedCrossRefGoogle Scholar
  6. 6.
    Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B et al (1996) A placebo-controlled multicentre study of auroanofin in the treatment of patients with corticosteroid-dependent asthma. J Allergy Clin Immunol 98: 317–324PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein JA (1983) Hydroxychloroquine for asthma (letter). Am Rev Resp Dis 128: 1100–1101PubMedGoogle Scholar
  8. 8.
    Roberts JA, Gunneberg A, Elliott JA, Thomson NC (1988) Hydroxychloroquine in steroid dependent asthma. Pulm Pharmacol 1: 59–61PubMedCrossRefGoogle Scholar
  9. 9.
    Charous BL (1990) Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. Ann Allergy 65: 53–58PubMedGoogle Scholar
  10. 10.
    Mullarkey MF, Blumenstein BA, Pierre Andrade W, Bailey GA, Olason I, Wetzel CE (1988) Methotrexate in the treatment of corticosteroid-dependant asthma. New Engl J Med 318: 603–607PubMedCrossRefGoogle Scholar
  11. 11.
    Shiner RJ, Nunn AL, Fan Chung K, Geddes DM (1990) Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 336: 137–140PubMedCrossRefGoogle Scholar
  12. 12.
    Marin GM (1997) Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients. Chest 112: 29–33PubMedCrossRefGoogle Scholar
  13. 13.
    Kuitert LM, Harrison AC (1991) Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. Thorax 46: 936–937PubMedCrossRefGoogle Scholar
  14. 14.
    Vallerand H, Cossart C, Milosevic D, Lavaud F, Leone J (1992) Fatal pneumocystis pneumonia in asthmatics patient treated with methotrexate. Lancet 339: 1551PubMedCrossRefGoogle Scholar
  15. 15.
    Gatnash AA, Connolly CK (1995) Fatal chickenpox pneumonia in an asthmatic patient on oral steroids and methotrexate. Thorax 50: 422–423PubMedCrossRefGoogle Scholar
  16. 16.
    Altz-Smith M, Kendall LGJ, Stamm AM (1987) Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med 83: 179–181PubMedCrossRefGoogle Scholar
  17. 17.
    Keegan JM, Byrd JW (1988) Nocardiosis associated with low dose methotrexate for rheumatoid arthritis (letter). J Rheumatol 15: 1585–1586PubMedGoogle Scholar
  18. 18.
    Asmundsson T, Kilburn KH, Lazzlo J, Krock CJ (1971) Immunosuppressive therapy of asthma. J Allergy 47: 136–147PubMedGoogle Scholar
  19. 19.
    Hodges NG, Brewis RAL, Howell JBL (1971) An evaluation of azathioprine in severe chronic asthma. Thorax 26: 734–739PubMedCrossRefGoogle Scholar
  20. 20.
    Kahan BD (1989) Cyclosporin. New Engl J Med 321: 1725–1738PubMedCrossRefGoogle Scholar
  21. 21.
    Cirillo R, Triggiani M, Sirih et al (1990) Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 144: 389–397Google Scholar
  22. 22.
    Alexander AG, Barnes NC, Kay AB (1992) Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339: 324–328PubMedCrossRefGoogle Scholar
  23. 23.
    Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B, Pajak A, Szczeklik A (1995) Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 8: 1091–1099PubMedCrossRefGoogle Scholar
  24. 24.
    Lock SH, Kay AB, Barnes NC (1996) Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 153: 509–514PubMedGoogle Scholar
  25. 25.
    Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, Kay AB (1997) Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 52: 447–452PubMedCrossRefGoogle Scholar
  26. 26.
    Bussel JB, Szatrowski TP (1995) Uses of intravenous gammaglobulin in immune haematologic disease. Immunol Invest 24: 451–456PubMedCrossRefGoogle Scholar
  27. 27.
    Mazer BD, Gelfand EW (1991) An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 87: 976–983PubMedCrossRefGoogle Scholar
  28. 28.
    Jakobsson T, Croner S, Kjellman N, Pettersson A, Vassella C, Bjorksten B (1994) Slight steroid sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy 49: 413–420PubMedCrossRefGoogle Scholar
  29. 29.
    Valacer DJ, Kishiyama JL, Com B, Richmond GW, Bacot B, Glovsky M, Stiehm R, Stocks J, Rosenberg LA, Tonetta SA (1997) A multi-center, randomized, placebo-controlled trial of high dose intravenous gammaglobulin (IVIG) for oral corticosteroid-dependent asthma. Am J Respir Crit Care Med 155: A659Google Scholar
  30. 30.
    Pallares DE, Marshall GS (1992) Acute aseptic meningitis associated with administration of intravenous immunoglobulin. Am J Paediatr Hematol Oncol 14: 279–281CrossRefGoogle Scholar
  31. 31.
    Blasczyk R, Westhoff U, Grosse-Wilde M (1993) Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 341: 789–790PubMedCrossRefGoogle Scholar
  32. 32.
    Boitard C, Bach JF (1989) Long-term complications of conventional immunosuppressive treatment. Adv Nephrol 18: 335–354Google Scholar
  33. 33.
    Muranaka M, Nakajima K, Suzuki S (1981) Bronchial responsiveness to acetylcholine in patients with bronchial asthma after long-term treatment with gold salts. J Allergy Clin Immunol 67: 350–356PubMedCrossRefGoogle Scholar
  34. 34.
    Szczeklik A, Nizankowska E, Sladek K (1992) Cyclosporin and asthma (letter). Lancet 339: 873PubMedGoogle Scholar
  35. 35.
    Mullarkey MF, Lammart JK, Blumenstein BA (1990) Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 112: 577–581PubMedGoogle Scholar
  36. 36.
    O’Riordan TG, Iacono A, Keenan RJ et al (1995) Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 151: 516–512PubMedGoogle Scholar
  37. 37.
    Chang JY, Seagal SN, Bansdach C (1991) FK506 and rapamycin: novel pharmacological probes of the immune response. Trends Pharmacol Sci 12: 218–222PubMedCrossRefGoogle Scholar
  38. 38.
    Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC (1998) Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (kelix-imabb) in chronic severe asthma. Lancet 352: 1109–1113PubMedCrossRefGoogle Scholar
  39. 39.
    Corrigan CJ, Bungre JK, Assoufi B, Cooper AE, Seddon H, Kay AB (1996) Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur Respir J 9: 2077–2086PubMedCrossRefGoogle Scholar
  40. 40.
    Mullarkey MF (1997) Methotrexate revisited. Chest 112: 1–2PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • Li Cher Loh
    • 1
  • Neil C. Barnes
    • 1
  1. 1.Department of Respiratory MedicineThe London Chest HospitalLondonUK

Personalised recommendations